Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures
L. Broadbent, H. Guo Parke, L. J. Ferguson, A. Miller, M. D. Shields, L. Detalle, U. F. Power
This study compares the therapeutic efficacy of ALX-0171 and palivizumab against RSV infection in a human bronchial epithelial cell model, showing ALX-0171 is more potent at neutralizing virus but less effective at reducing viral genomic copies.
Antimicrobial Agents and Chemotherapy · Jan 27, 2020Peer-reviewedMicrobiology